Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Temsirolimus controlled metastatic advanced renal cell carcinoma for over 4 years: a case study.

Takayama T, Furuse H, Kai F, Sugiyama T, Ozono S.

Med Oncol. 2013;30(2):563. doi: 10.1007/s12032-013-0563-2. Epub 2013 Apr 3.

PMID:
23549866
2.

Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.

Sun Y, Rha S, Lee SH, Guo J, Ueda T, Qin S, Naito S, Cincotta M, Tokushige K, Akaza H.

Jpn J Clin Oncol. 2012 Sep;42(9):836-44. doi: 10.1093/jjco/hys110. Epub 2012 Jul 26.

PMID:
22844126
3.

Temsirolimus in renal cell carcinoma.

Otto T, Eimer C, Gerullis H.

Transplant Proc. 2008 Dec;40(10 Suppl):S36-9. doi: 10.1016/j.transproceed.2008.10.006.

PMID:
19100905
4.

Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases.

Areses MC, Herranz UA, Ferrán BB, Mateos LL, González JG, López RL.

Med Oncol. 2012 Jun;29(2):795-8. doi: 10.1007/s12032-011-9976-y. Epub 2011 May 11.

PMID:
21560067
5.

[Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma].

Miyake H, Fujisawa M.

Hinyokika Kiyo. 2012 Nov;58(11):651-4. Japanese.

6.

Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.

Lamm W, Vogl UM, Bojic M, Zielinski C, Klingler C, Kramer G, Schmidinger M.

Acta Oncol. 2012 Jan;51(1):101-6. doi: 10.3109/0284186X.2011.589404. Epub 2011 Jul 8.

PMID:
21736504
7.

[Treatment of hemodialyzed patient by targeted therapy in metastatic renal cell carcinoma: a case report].

Kato S, Shibamori K, Hiyama Y, Tabata H, Matsuda Y, Takei F, Yanase M.

Nihon Hinyokika Gakkai Zasshi. 2013 Jul;104(4):605-8. Japanese.

PMID:
23971369
8.

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.

Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G.

Med Oncol. 2009;26(2):202-9. doi: 10.1007/s12032-009-9177-0. Epub 2009 Feb 20.

PMID:
19229667
9.

Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma.

Rodríguez Faba O, Breda A, Rosales A, Palou J, Algaba F, Maroto Rey P, Villavicencio H.

Eur Urol. 2010 Aug;58(2):307-10. doi: 10.1016/j.eururo.2010.03.005. Epub 2010 Mar 12.

PMID:
20347211
10.

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.

Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R.

Oncologist. 2010;15(4):428-35. doi: 10.1634/theoncologist.2009-0178. Epub 2010 Mar 23.

11.

Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.

Afshar M, Pascoe J, Whitmarsh S, James N, Porfiri E.

Drug Des Devel Ther. 2014 Dec 17;9:13-9. doi: 10.2147/DDDT.S73686. eCollection 2015.

12.

Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.

J Clin Oncol. 2007 Sep 1;25(25):3958-64.

PMID:
17761980
13.

Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.

Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J.

Semin Oncol. 2009 Dec;36 Suppl 3:S26-36. doi: 10.1053/j.seminoncol.2009.10.013. Review.

PMID:
19963097
14.

Temsirolimus: in advanced renal cell carcinoma.

Simpson D, Curran MP.

Drugs. 2008;68(5):631-8. Review.

PMID:
18370442
15.

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial.

N Engl J Med. 2007 May 31;356(22):2271-81.

16.

Temsirolimus in the treatment of advanced renal cell carcinoma.

Gore ME.

Ann Oncol. 2007 Jul;18 Suppl 9:ix87-8. Review. No abstract available.

PMID:
17631601
17.

Temsirolimus: a safety and efficacy review.

Bukowski RM.

Expert Opin Drug Saf. 2012 Sep;11(5):861-79. doi: 10.1517/14740338.2012.713344. Epub 2012 Aug 6. Review.

PMID:
22861825
18.

Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.

Malizzia LJ, Hsu A.

Clin J Oncol Nurs. 2008 Aug;12(4):639-46. doi: 10.1188/08.CJON.639-646. Review.

PMID:
18676330
19.

Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.

Figlin RA.

Nat Clin Pract Oncol. 2008 Oct;5(10):601-9. doi: 10.1038/ncponc1173. Epub 2008 Jul 8. Review.

PMID:
18607393
20.

Brain metastasis in a patient with a sarcomatoid variant RCC with well-controlled extracerebral metastases by temsirolimus.

Kikuno N, Kennoki T, Fukuda H, Matsumoto Y, Tsunoyama K, Ban S, Satoh H, Ryoji O.

Anticancer Res. 2012 Aug;32(8):3443-7.

PMID:
22843928

Supplemental Content

Support Center